Isabelle Bedrosian

Implications of the COMET Trial for the Management of Atypical Ductal Hyperplasia.

Implications of omitting sentinel lymph node biopsy on adjuvant decision making for patients with small breast cancers.

ASO Author Reflections: Omission of Routine Surgery for Atypical Ductal Hyperplasia: Are We Getting Closer?

Trends in Atypical Ductal Hyperplasia Diagnosis and Upgrade: A 20-Year Experience and Impact of MRI Use on Upgrade Rates.

Sequence of therapy impact on older women with comorbidities and triple-negative or HER2-positive breast cancer.

ASO Visual Abstract: Implications of the COMET Trial on Management of Atypical Ductal Hyperplasiass

Data from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S7 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Table S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S8 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Tables S2-13 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S6 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Table S5 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Supplementary Table S4 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Supplementary Fig. S3 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Table S3 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Supplementary Fig. S4 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

ASO Visual Abstract: Trends in Atypical Ductal Hyperplasia Diagnosis and Upgrade—A Twenty-Year Experience and Impact of MRI Use on Upgrade Rates

Supplementary Table S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Supplementary Fig. S5 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S2 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Fig. S1 from Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer

Supplementary Table S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Supplementary Fig. S1 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma <i>In Situ</i>

Germline Testing in Patients With Breast Cancer: ASCO–Society of Surgical Oncology Guideline

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.

Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline Q and A.

Survival outcomes after omission of surgery for ductal carcinoma in situ.

Supplementary Fig. S2 from Phase II Trial of Nelipepimut-S Peptide Vaccine in Women with Ductal Carcinoma in Situ